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Tau is an intrinsically disordered, heat stable, and highly soluble protein found primarily in the 
axons of the central nervous system. It belongs to the family of structural microtubule-associated 
proteins, the major function of which is promoting and stabilizing microtubule assembly. 
However, modifications to the protein generate insoluble toxic oligomers of aggregated tau which 
are amyloid in nature. This modification renders them ineffective in binding to tubulin to stabilize 
microtubule assembly. Aggregates of tau are pathological hallmarks of many neurodegenerative 
disorders, collectively known as tauopathies. Some of the most well-known tauopathies are Pick’s 
disease (PiD), progressive supranuclear palsy (PSP), corticobasal neurodegeneration (CBD), and 
Alzheimer’s disease (AD). AD is the 6th leading cause of death in the USA and is the most 
prevalent tauopathy. There are only five FDA approved drugs that can arrest the cognitive decline 
and other symptoms of AD temporarily, but they do not reverse or inhibit the pathology of the 
disease. The disease therefore continues to progress, and cognitive functions decline faster when 
the drugs lose their effectiveness. There is a general consensus that therapies that reduce pathology 
would be beneficial for treating the disease. AD is characterized by two neuropathological 
hallmarks – extracellular senile plaques, which are aggregates of amyloid  peptide, and 
intracellular neurofibrillary tangles, which are composed of tau aggregates. Initially, much of the 
emphasis for drug discovery for AD was focused on inhibiting or reversing the amyloid senile 
plaque pathology. This focus was due to the observation that familial forms of early onset AD are 
associated with mutations which enhanced the formation of senile plaques. Additionally, the 
number of dementia cases involving senile plaques outnumbers dementia cases with pure 
tauopathies. Recent failures of drugs targeting amyloid accumulation for the treatment of AD and 
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new evidence further strengthening the association of tau pathology with neurodegeneration and 
AD cognitive impairment have placed importance on the development of tau-based therapeutics.  
This report discusses the current state of therapies and drugs that are available and are being 
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Chapter 1. Introduction 
1.1. Microtubules and microtubule associated proteins 
Microtubules are essential for a variety of cellular functions such as cell motility, transport, 
cell shape and polarity and mitosis. Microtubules are built from heterodimers of  and  tubulin 
monomers. -tubulin belongs to the family of tubulins but does not assemble into microtubules, 
and instead is required for nucleating the polymerization of microtubules in vivo [1]. There are 
many classes of proteins which interact with tubulins, some of which are listed below.  
The microtubule associated proteins, or MAPs, whose primary function is to stabilize and 
promote microtubule assembly by binding to microtubules are known as structural MAPs. 
Representatives structural MAPs are MAP1a, MAP1b, MAP2a, MAP2b, MAP4, tau protein, and 
a 205 kDa MAP [2].  
A second broad classification of MAPs are the motor proteins kinesin and dynein. The 
primary function of motor proteins is generation of movement along microtubules using chemical 
energy generated from ATP hydrolysis [2]. Kinesin transports cargo of membrane bound vesicles, 
proteins and other organelles along the microtubules towards the positive end, and dynein 
transports towards the negative end of the microtubule. Microtubules grow from their positive end 
[2] and therefore, kinesin transports proteins which are necessary for it to grow from the positive 
end. Dynein can transport different organelles from the endoplasmic reticulum to the golgi and 
such transport can transmit signals to different parts of the cell [3]. 
The third major category of microtubule associated proteins are the microtubule plus-end 
tracking proteins (+tips) [4].They are a structurally and functionally diverse groups of proteins that 
are distinguished by their specific accumulation at the plus end of the microtubule tips [5-7]. Plus 
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end tip-proteins mainly stabilize the plus end of the microtubules. They help maintain the shape 
of the microtubule network and play an essential role during cell motility and morphogenesis [5]. 
Another category of microtubule associated proteins is the  tubulin ring complex (TuRC) 
and the proteins associated with it [8]. TuRC is a ring shaped structure which is comprised of -
tubulin and associated proteins that nucleate microtubule assembly in vivo [9-11] and in vitro [12]. 
1.1.1. Tau Protein Structure 
In 1975, “tau” was first identified by Weingarten and his colleagues when it co-purified 
with tubulins from porcine brain extracts. Tau, an intrinsically disordered and heat stable protein, 
was found to promote and stabilize microtubule polymerization [13].  
In humans, tau is encoded by a gene on chromosome 17 [14] and it is expressed as different 
isoforms due to alternative splicing of the pre-mRNA in the central nervous system (CNS). Tau is 
primarily localized in the neurons of the CNS in the adult human brain. Full length tau (2N4R) is 
comprised of 441 amino acids and is the longest isoform of tau found in the adult human brain 
[15-17] (Figures 1 and 2). Within the 441 residues, about 85 of them can be phosphorylated (45 of 
which are serines, 35 are threonines and 5 are tyrosines [18-20]).  
In an adult human brain, alternative splicing of exons 2, 3 and 10 generates 6 different 
isoforms of tau ranging in length from 352 to 441 amino acids [16, 17] (Figure 1). These differ in 
part by the presence of either three or four carboxy terminal tandem repeat sequences of 31-32 




















Figure 1: Structure of human tau gene and the 6 different isoforms that are generated by alternative splicing in the 
CNS. Figure modified from “Tau mis-splicing in the pathogenesis of neurodegenerative disorders Sun et.al. (2016)" 
A tau protein can either have three microtubule binding repeat regions (3R) or four microtubule 
binding repeat regions (4R). Three isoforms of 3R tau are generated by the exclusion of exon 10 
during alternative splicing. The other three isoforms of 4R tau are generated when they have four 
binding repeat regions including the one encoded by exon 10 [21] (Figure 1). The microtubule 
binding motifs are highly conserved structures which are 18 amino acids long. They are separated 




R1, R2, R3, R4 – Different microtubule binding repeats. 





















Additionally, the isoforms of 3R and 4R tau isoforms differ as a result of alternative 
splicing of exons 2 and 3. Exclusion of the region encoded by exons 2 and 3 generates 0N tau. 
Inclusion of 29 amino acids encoded by exon 2 generates 1N tau and inclusion of 58 amino acids 
encoded by both exons 2 and 3 generates 2N tau (Figure 1) [22]. The N terminal region of tau is 
dominated by the presence of hydrophilic and charged residues that are mostly acidic in nature. 
The acidic nature of the N terminal region is due to the polypeptide sequences encoded by exons 
2 and 3.   
The microtubule binding repeat region (MTBR) of tau is flanked by a basic proline rich 
domain (Figure 2) [23]. The proline rich region is subdivided into P1 and P2 [24]. Tau is 
developmentally regulated. In the fetal brain only 0N3R isoforms are observed [15, 21]. In the 
Figure 2: Structure of a 2N4R tau isoform found in the adult human brain. Illustrated are the N terminal region, Proline rich 
region, Microtubule binding repeat region and the C terminal region. The bold black P in the magnified proline rich region 
are the prolines. E2 and E3 denotes the stretch of amino acids encoded by exons 2 and 3 respectively; Modified from 
“Structure and pathology of tau protein in Alzheimer’s disease, Krestova et al. (2012)” 
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adult human brain, roughly similar ratios of 3R to 4R tau isoforms are found [23]. The 1N, 0N and 
2N isoforms account for 54%, 37% and 9% of the total amount of tau, respectively [25].  
Although tau is a natively unfolded protein with an overall low content of secondary 
structure, there is evidence that tau has the propensity to fold into a paperclip conformation when 
it is free in the cytoplasm [26]. The paperclip conformation generally occurs when tau dissociates 
from microtubules [16]. In this conformation, the C terminus of tau folds over the microtubule 
binding domain and the N terminus folds over the C terminus, thus the N and C terminals are near 
each other (Figure 3) [27]. This conformation has been speculated to protect the MTBR of tau 
from getting abnormally modified.  
An isoform of tau with about 400 additional amino acids is found exclusively in the 
peripheral nervous system (PNS) and is known as “big tau”. The higher molecular weight is a 
result of the inclusion of exon 4a in the amino terminal half of the tau protein [28]. Since its 
discovery more than 30 years ago, many functions of tau have been characterized based on its 













Tau in paperclip conformation 
When tau is bound to microtubule 
Figure 3: Structure of tau when bound to microtubules and when it is free in the cytoplasm. The red box 
denotes is the microtubule binding repeats regions.  
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1.1.2. Tau function 
Dimers of alpha and beta tubulin are required to polymerize and form microtubules. Tau 
binds to the microtubules at the interdimer interface through repetitive short sequence motifs (R1, 
R2, R3 and R4 shown in Figures 1 and 2) in the C terminal region and promotes their nucleation 
to form microtubules in vitro [29, 30]. Tau can be crosslinked to Lys 336 and Lys 338 of alpha 
tubulin [18].  
The N terminal region of tau is also referred to as the projection domain. It is so called 
because it projects out from the surface of the microtubule and interacts with other cytoskeletal 
elements and the neuronal plasma membrane [31]. Although the projection domain does not 
directly bind to microtubules, it influences attachment and spacing between microtubules and other 
cell components [23, 32].  
The proline rich region (Figure 2) is involved in interactions of tau with actin and it also is 
associated with the bundling of F-actin (filamentous actin) [33]. F-actin has a structural, 
mechanical, and enzymatic role inside the cells and is involved in cell migration. Thus, tau 
influences bundling of filamentous actin and cross linking of cellular cytoskeleton components 
[33]. The Src kinases Lck, Fgr and Fyn bind to the proline rich region of tau protein. Certain other 
proteins such as bridging integrator (BIN1) phospholipase C (PLC) 1, and PLC 2 also bind to 
this region [34]. Tau has been observed to bind to cSrc and Fyn in cell culture models. This 
interaction of the proline rich region of tau with cSrc drove platelet-derived growth factor 
stimulation followed by cSrc mediated-actin rearrangements [35]. Tau binds phospholipase C in 
human neuroblastoma cells SH-SY5Y [36]. Activation of PLC is facilitated in the presence of 
fatty acids such as arachidonic acid [37]. However, under cell free conditions and in the presence 
of unsaturated fatty acids it has been observed that tau activates PLC [37]. Higher levels of 
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arachidonic acid are observed in the brain of AD patients and related mouse models [38]. Thus, 
together tau and arachidonic acid may increase signaling through the PLC pathway and hence, 
may have a role to play in neuronal cell signaling. Apart from structurally stabilizing the 
microtubules, tau also interacts with histone deacetylase 6, HDAC6 [39]. Tau can bind to as well 
as inhibit histone deacetylase 6 which deacetylates tubulin and may regulate microtubule stability 
[40]. Inhibition of histone deacetylase 6 also prevents induction of autophagy by inhibiting 
proteasome function [40].  In AD brains, the level of HDAC6 is significantly decreased [39].  
Inhibition of HDAC6 interacting with tau protein reduced phosphorylation of tau at Thr231 [41]. 
These data suggest that inhibition of HDAC6 leads to modifications of tau [30, 31].  
Tau plays a major role in promoting and stabilizing microtubule assembly. However, 
modifications to tau such as hyperphosphorylation and deacetylation results in the formation of 
toxic species, and influences tau to dissociate from the microtubules which might result in many 
neurodegenerative disorders such as Alzheimer’s disease, Pick’s disease and other related 
dementias [42].  
 
Chapter 2. Tau and diseases 
2.1. Modification of tau seen in neurodegenerative disorders. 
Although tau has a low propensity to form secondary or tertiary structure, under 
pathological conditions it forms highly ordered aggregates with high  sheet content. Abnormally 
phosphorylated aggregated tau has been observed in the core of paired helical filaments (PHFs) 
which are components of neurofibrillary tangles (NFTs) (Figure 4). Modified forms of tau have 
been observed in AD patients and other tauopathies [43-45]. Aggregates of tau are found in many 
other neurodegenerative disorders such as Pick’s disease (PiD), progressive supranuclear palsy 
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(PSP), chronic traumatic encephalopathy (CTE), and corticobasal neurodegeneration (CBD). The 
conversion from tau monomers to pathological aggregated tau is believed to be a multistep process 
[42, 46]. It has been hypothesized that abnormally high levels of modifications of tau leads to 
neurodegeneration as it enhances the formation of pathological tau as found in diseases [42]. 
 
 
Figure 4: Schematic of abnormal modification of tau leading to the formation of NFTs in AD. 
 
2.1.1. Hyper phosphorylation of tau 
Tau binding to microtubule is modulated by phosphorylation at Y394 and S396 [14]. 
However, phosphorylation of the KXGS motifs within the microtubule binding motifs strongly 
reduces the binding of tau to the microtubules in vitro [37] and in vivo [38-40]. Since dynamic 
site-specific tau phosphorylation strongly influences tau function and localization, aberrant 
phosphorylation of tau might be the key event in tau pathology. Binding of hyperphosphorylated 
tau with normal tau has been revealed by in vitro kinetic studies [41, [47]. Phosphorylation at 
Ser199/Ser202/Thr205, Thr212, Thr231/Ser235, Ser262/Ser356, and Ser422 converts tau into an 
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inhibitory molecule that interacts with and sequesters normal non-phosphorylated tau away from 
microtubules [41, 47]. Hyperphosphorylated tau will bind with more affinity to non-
hyperphosphorylated tau as phosphorylation reduces the total positive charge on the tau protein. 
Therefore, similarly charged tau will repel each other and hyperphosphorylated tau will bind to 
normal tau with more affinity because of its more positively charged character. Aggregation of tau 
into filaments is encouraged by phosphorylation of the three sites, Thr231, Ser396 and Ser422. In 
vitro, phosphorylation of Ser 396 and Ser 404 generates pro-fibrillogenic tau [48].  
 
2.1.1.1. Kinases influence tau phosphorylation in vitro, in vivo and in cell-culture based 
models. 
2.1.1.1.1. GSK3 
Out of the many kinases present in the brain, several have been reported to interact with 
tau [49]. One such kinase is glycogen synthase kinase 3  (GSK-3). This kinase is expressed at 
high levels in the brain and it localizes in neurons [50]. GSK3 associates with microtubules and 
when it is overexpressed, phosphorylation of tau is seen to increase [41, 51, 52]. Lithium has long 
been used to treat bipolar disorders. It was hypothesized by Hong et al., that lithium would inhibit 
GSK3 and therefore reduce the hyperphosphorylation of tau observed in AD [53]. Treatment of 
NT2N neuronal cells with lithium not only decreased tau phosphorylation, but it also enhanced 
binding of tau to microtubules [53]. In studies on transgenic mouse expressing mutant tau, 




Another kinase potentially associated with tau in vivo is cyclin dependent kinase 5 (cdk5) 
[55]. cdk5 is a unique member of the cdk family that is activated by interactions with non-cyclins 
p35 and p39, which are regulatory proteins expressed in post-mitotic neurons [56]. In vitro, tau is 
a substrate for cdk5, and cdk5 can phosphorylate most of the phosphorylation sites of tau which 
are phosphorylated by GSK3 [57]. Overexpression of cdk5 and p25 (a product formed by the 
truncation of p35 that accumulates in the brains of AD patients), but not p35, increases cdk5 
activity, but it does not in turn increase tau phosphorylation in situ [58].  
 There are conflicting reports regarding the role played by cdk5 in tau phosphorylation. 
Studies with transgenic mice overexpressing mutant tau have shown that cdk5 can phosphorylate 
tau [59]. However, in studies conducted with triple mutant transgenic mouse models 
overexpressing human cdk5, its activator p35 and human protein tau, cdk5 does not result in 
increased tau phosphorylation [60]. Knocking out p35 significantly decreases cdk5 activity, but 
increased tau phosphorylation is observed [61]. In the same knockout mouse model GSK3 was 
increased by 50% which explains the increased tau phosphorylation [61].  
 
2.1.1.1.3. MARK 
Microtubule affinity regulating kinase (MARK) might play an important role in 
phosphorylating tau in models of transgenic mice expressing tau. MARK phosphorylates all the 
four KXGS motifs particularly Ser 262, Ser 293, Ser 324, and Ser 356 [62], which are present in 
and around the microtubule binding repeat of tau as well as in other microtubule associated 
proteins, and this results in detachment of tau from microtubules and their destabilization [62]. In 
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cell culture models, MARK appears to regulate tau phosphorylation and influence the growth of 
neurites and neuronal polarization in N2a cells [63].  
2.1.1.1.4. Other kinases 
CK1 is a casein kinase and it has been seen to localize with tau aggregates in AD [10, 57]. 
Several isoforms of CK1 exists which can phosphorylate tau. CK-1  (an isoform of CK1 generated 
by splicing) phosphorylates tau at Ser202/Thr205 and Ser396/Ser404 in vitro [58, 59] and 
colocalizes with NFTs in AD, PSP, and PiD [60]. Moreover, the mRNA of CK1  is upregulated 
in AD brains [60].  The 5 tyrosine phosphorylation sites of tau are phosphorylated by SFKs (Src 
family kinases) such as Src, Lck, Fyn and c-Abl kinase [61].  
2.1.1.2. Phosphatases  
Phosphatases interacting with phosphorylated tau resulted in the reduction of aggregates and 
restoration of the microtubule binding function of tau, promoting microtubule stabilization and 
polymerization [64].  In general, PP2A (protein phosphatase 2A) is responsible for 70% of the 
cellular phosphatase activity [64] in the human brain. In AD brains, a significant reduction of the 
PP2A activity can be observed [64], which suggests that an imbalance of phosphatases and kinases 
plays a major role in the generation of abnormally phosphorylated tau isoforms. It has also been 
hypothesized that downregulation of phosphatases might be due to phosphatase inhibitors present 
in the brain. The PP2A inhibitor I1PP2A purified from bovine kidney [65] and human brain [66] was 
found to inhibit purified preparations of PP2A [66]. Tanimukai et al., found a significant increase 
in the mRNA expression of I1PP2A and I2PP2a at neocortical levels in AD, as compared to control 
cases, by performing in situ hybridization and immunohistochemical studies [67]. On performing 
double histochemical studies, they also found that inhibitors of PP2A and PP2A colocalized with 
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abnormally phosphorylated tau [67] suggesting that inhibition of phosphatase PP2A results in 
abnormal phosphorylation of tau protein as seen in AD. 
 In summary, evidence collected over the years indicates that overexpression of tau kinases 
such as GSK3 and cdk5, and inhibition of phosphatases such as PP2A results in the 
hyperphosphorylation of tau, which subsequently results in formation of toxic tau oligomers 
(discussed below). Although aggregated tau is heavily phosphorylated in human brains, it is not 
yet proven that all phosphorylated tau is in aggregates or will eventually aggregate [68]. The ability 
of tau to interact with microtubules is reduced upon phosphorylation. However, it is still unknown 
whether phosphorylation acts as a trigger for tau aggregation.  
2.1.2. Tau aggregation 
 Tau aggregates are formed in two steps – nucleation and elongation. Tau monomers and 
dimers form a nucleation center and when a critical cluster size is obtained, the result is tau 
oligomerization in a dose and time dependent manner [69]. Tau oligomers then form longer fibrous 
aggregates with a cross  structure similar to amyloid aggregates [70]. It has been demonstrated 
that the propensity to form aggregates is influenced by the hexapeptide motifs present in the second 
and third microtubule binding repeat regions of tau [71]. 
Tau filaments isolated from AD brains and those induced in vitro share a cross  structure 
which is similar to the amyloid fibrils [72]. It has been hypothesized that the hexapeptide motif 
VQIVYK (Val-Gln-Ile-Val-Tyr-Lys, also termed as PHF6) located at the beginning of the third 
microtubule binding repeat and encoded by residues 306-311, and VQIINK (Val-Gln-Ile-Ile-Asn-
Lys, also termed as PHF6*) located at the N terminal region of the microtubule binding repeat 
region 2 and encoded by residues 275-280 [73] (Figure 1) play a major role in the formation of tau 
aggregates. PHF6 and PHF6* have the propensity to self-assemble and form cross beta sheet 
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structure. Solid state nuclear magnetic resonance of microtubule repeats 1, 3 and 4 showed the 
presence of three beta strands, one from each repeat [74, 75]. A part of the core of PHFs 
corresponds to residues 306-324 located in MTBR 3 [76] demonstrating that the hexapeptide 
repeat regions form the core of tau aggregates.  The hexapeptide regions of tau self-assemble in 
the absence of chemical stimuli [23, 77, 78], and they form aggregates under similar conditions as 
does full-length tau [79].   
 Certain missense mutations in tau, such as P301L, enhance the propensity of tau to form 
beta sheets and render the tau isoforms more prone to aggregation. Similarly, it has been observed 
that self-assembly of tau at VQIVYK and VQIINK motifs can become accelerated if there are 
point mutations around them, such as are observed in P301L and K280 mutants [73, 79]. At the 
same time, if unfavorable amino acid substitutions are made in the hexapeptide motifs, such as 
proline residues which disrupt the beta sheet structure, this can render tau incompetent for 
assembly [80]. Crystallization of fibril forming motifs has shown that the hexapeptide motifs 
VQIVYK and VQIINK are necessary as well as sufficient for tau fibrillization [81]. Therefore, the 
above data attest to the fact that hexapeptide motifs play a major role in the assembly of tau 
monomers into insoluble aggregates in cells.  
 When tau is phosphorylated at serines, threonines and tyrosines, it becomes more 
negatively charged. Similarly, other post-translational modifications such as acetylation neutralize 
the positively charged lysine residues [13]. These types of post-translational modifications result 
in the formation of a more negatively charged tau molecule or an overall reduction in the positive 
charge on tau. The charge alteration might impact overall binding of tau to microtubules, and may 
affect the folding capability of tau into the paper clip structure, therefore exposing the phosphatase 
activating domain present in the N terminal region of tau [82]. The phosphatase activating domain 
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activates GSK3 kinase. In AD brains higher levels of GSK3 are observed and this is also 
associated with abnormal phosphorylation of tau.  
 Mirbhaha et al. had observed that when tau aggregates are exogenously delivered or 
“seeded” in mice brains, propagation of those aggregates take place from one part of the brain to 
the other [84]. Tau inclusions at the injection sites were observed in the brain of P301S tau 
transgenic mice which were intracerebrally injected with brain extracts containing tau aggregates 
isolated from presymptomatic animals. It was suggested by the authors that when presymptomatic 
mice was intraperitoneally injected with brain extracts from P301S tau transgenic mice, cerebral 
tau inclusions were promoted in the presymptomatic mice [83]. Therefore, they concluded that 
aggregated tau can promote inclusion formation in the CNS of transgenic mice. These studies 
suggested that introducing seeds of tau aggregates into the brain results in the propagation of tau 
aggregates from the point of injection to other portions of the brain.   
 In AD, tau aggregates are found to be abnormally phosphorylated [84]. Abnormal 
phosphorylation of tau negatively impacts the ability of the protein tau to bind to microtubules. 
Conformational changes of tau can be observed as tau gets phosphorylated, and therefore this post-
translational modification - along with others such as truncation and glycosylation - can influence 
tau aggregation [84-86].  
2.1.3. Other post-translation modifications - truncation of tau 
 Proteolytic cleavage of tau protein has been identified in tauopathies such as PiD [87], AD 
[88], CBD and PSP [89]. A protease-resistant core of 12kDa and 9.5 kDa tau fragments from 
within the paired helical filaments (PHF) in AD brains were identified by the same antibody which 
recognized C terminally truncated tau at Glu391 position [90]. The protease resistant 12 kDa form 
of tau suggested that truncation might be the mechanism that leads to the formation of forms of 
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tau that are prone to misfolding and self-assembly [91].  This view was supported when truncated 
tau was observed in association with the neurofibrillary pathology in AD brains [92]. These were 
immunolabelled with monoclonal antibody MN423 which specifically recognized Glu391 truncated 
tau associated with neurofibrillary tangles found in AD [48]. DC11 is also a truncation dependent 
conformational antibody that recognizes abnormal tau in AD, but not normal functional tau in 
control brains [93]. Recombinant tau proteins truncated either at the N terminus or at both N and 
C termini were recognized by DC11 [93]. This evidence indicated that both N- and C-terminally 
truncated forms tau are present in AD brains and are likely involved in pathological conformations 
of tau.   
It is well-known that abnormal proteolytic cleavage of proteins is a common observation 
during aging as well as being associated with neurodegeneration [94]. Caspase, which belongs to 
the family of serine-aspartyl proteases, is involved in a majority of such truncation of proteins. Tau 
protein has been observed to be cleaved by caspase proteases at multiple sites. Caspase-3 cleaves 
tau at the carboxy-terminal residue of aspartic acid-421 (Asp421) [94]. Tau truncated at Asp421 by 
caspase 3 was recognized by a monoclonal antibody Tau C3 [88]. It was also observed that 
truncated tau assembled more rapidly and more extensively in vitro [88] suggesting that truncation 
of tau at Asp421 can result in assembly of tau monomers into filaments as observed in AD. 
In vitro studies have revealed that both Glu391 and Asp421 truncated tau has a higher 
propensity to form aggregates than full length tau [95]. Insoluble lysates from AD brains are found 
to be enriched with Asp421 and Glu391 truncated isoforms of tau. Tau truncated at Asp421 colocalizes 
with tangles in AD brain as well as in neurofibrillary tangles that are induced in vitro [88]. 
Expression of truncated tau151-391 including 3 or 4 microtubule repeats in transgenic mouse brains 
induces neurofibrillary pathology resembling that of human tau pathology [96, 97]. Rats which 
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express truncated tau151-391 with 3R or 4R repeats exhibit pathological features such as tau 
phosphorylation with increasing age [97]. When sarkosyl insoluble tau from rat brains expressing 
Tau151-391 was extracted, truncated forms of tau were seen to co-aggregate with endogenous rat tau 
[96]. This suggested that tau truncation influences misfolding of normal tau which eventually is 
responsible for the generation of tangles in AD and other tauopathies [13].  
The mitochondria derived from synaptosomes of AD patients are enriched for truncated 
tau 26-230 (NH2 htau). The truncated tau might be the reason for the altered function and quality 
control of mitochondria at the synapses [98]. The studies conducted by the authors showed that 
excessive mitochondrial turnover and NH2 htau-induced in vitro neuronal death might be related. 
This suggested that truncated tau may contribute to synaptic dysfunction in AD which can be 
induced by the aberrant recruitment of parkin and UCHL-1 in the mitochondria. Recruitment of 
these proteins in the mitochindria makes them prone to unwanted autophagic clearance [98].  
Tau also undergoes certain other post translational modifications such glycosylation [97], 
ubiquitination [99], SUMOylation [100], nitration [101] and oxidation, which may indirectly 
facilitate tau aggregation [102], potentially by modifying tau conformation. 
2.2. Are the modifications of tau protein toxic or protective? 
 Loss of function as well as toxic gain of function of tau protein has been observed in many 
neurodegenerative disorders [103]. Post-translational modifications of tau, such as abnormal 
phosphorylation and truncation, leads to the sequestration of tau into aggregates, which results in 
an inability to bind to tubulin to promote microtubule assembly [102]. 
A study has shown that tau aggregates in frontotemporal dementia impair proteasome 
activity [104]. Myeku et al. working with the mouse model rTg4510 expressing the P301L 
mutation in tau observed that there was decrease in proteasome activity with the increase in tau 
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aggregation [105]. The authors crossed a tauopathy mouse model with a mouse which 
overexpressed a transgenic reporter for proteasome activity and verified that indeed proteasome 
defects were related to tau aggregation [105]. When they immunoprecipitated proteasome 
components with tau from the brains of the mice model they saw that association of tau with 
proteasomes increased with age and severity of the disease [105]. This study demonstrated that 
modifications to otherwise benign tau can result in impaired proteasome activity.   
 An example of toxic gain of function of tau has been demonstrated by a study conducted 
by Winkler et. al [106], in which they co-expressed human full-length tau along with truncated tau 
(3R tau151-421tau). Co-expression of full length tau with truncated tau (3R tau151-421tau) resulted 
in the failure of axonal transport, clumping of mitochondria, disruption of the Golgi apparatus, 
along with severe paralysis in mice. They generated an inducible mouse line overexpressing 
human 3R tau151-421(tau). They co-expressed it with wild type 4R or with wild type 3R tau or 
with mutant full length 4R P301S tau. In all the double mutants, severe cell damage and motor 
palsy was observed.  They also demonstrated mouse lines expressing human mutant full length 
P301S tau developed sarkosyl-insoluble tau inclusions, neurodegeneration, and paralysis [106]. In 
contrast, when truncated tau was no longer expressed in the mouse brain, functional and structural 
recovery was observed in mice expressing full length 4R tau. Also, double transgenic mice for full 
length 4R and 3R tau were unaffected [106].  
NH2-tau (Tau 26-230) has been isolated from tangles in the brains of AD patients and has 
decreased ability to bind to tubulin [23]. Tau 35 (E187-L441) is present in PSP and CBD but not 
in control brain samples [25]. Expression of Tau 35 in the transgenic mouse brain resulted in tau 
pathology, as well as cognitive and motor dysfunction in the mice [107]. Therefore, truncated tau 
has been shown to be neurotoxic and capable of playing a major role in tau pathology.  
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 A 33kDa N-terminally truncated tau (starting at residue Ser71 in 0N3R tau -Ser128 in 
2N4R tau) was found in tangles purified from human brain [108]. A 17kDa tau fragment was 
identified in the cerebellar granule neurons undergoing apoptosis [109]. Overexpression of tau45-
230 induced apoptosis in CHO cells and neurons. In an indirect study where formaldehyde was used 
to induce tau aggregation, it was observed that apoptosis took place in the neurotypic cell line SH-
SY5Y and also in rat hippocampal cells [110]. Therefore, it can be inferred from these observations 
that truncated tau has toxic properties that result in apoptosis of neurons.  
Surprisingly, it has also been found that tau monomers can be toxic to the neurons. In a 
study led by Nadine Ait Bouziad et al, it was found that tau interacts with cell membranes forming 
highly stable protein-phospholipid complexes which are toxic when added to hippocampal primary 
neurons [111]. The same study demonstrated that monomeric, fibrillar, and tau-phospholipid 
complexes induce cellular apoptosis when they are added exogenously to the hippocampal region 
of the transgenic mice brain [111]. Studies by Gomez-Ramos et al. proposed a mechanism by 
which monomeric tau can induce toxicity through muscarinic receptor-induced liberation, where 
the ligand (tau) binds to the receptor which causes the liberation of Ca2+ ions. [112]. On the other 
hand, tau oligomers induce toxicity by interacting with cell membranes [113], pore formation 
[113], facilitated endocytosis [114], and deleterious interactions with neuronal spines [111, 115]. 
Therefore, this suggested that tau, when truncated or aggregated, as well as certain forms of 
monomeric tau, can be toxic to neurons.  
 However, the presence of tau aggregates or the “toxic” oligomers in the Alzheimer induced 
mice brain or even in humans who did not suffer from any tauopathy raises a doubt regarding the 
toxicity of tau aggregates.  In most of the studies conducted with Drosophila models of tauopathy, 
NFTs are not formed even though neurodegeneration had already started to take place [106-110].  
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There is evidence that suggests NFTs are not sufficient for toxicity [106-110].  Mouse models 
which conditionally expresses human tau (tau 0N4R-P301L) do not form toxic aggregates of tau 
either [111]. These mouse models develop NFTs with age and consequently undergo neuronal loss 
and progressive motor deficits [111]. When tau expression is switched off after the formation of 
NFTs, memory improves, and cell loss is stabilized, however NFTs continue to accumulate [111]. 
Hence, this experiment suggests that the presence of NFTs does not result in neurodegeneration.  
A study attempting to determine whether filamentous tau is toxic or protective, found that 
tau filaments appeared “healthy” in terms of nuclear morphology suggesting that polymerized 
protein might be neuroprotective [116].  
Toxic oligomers of tau have been observed in many neurodegenerative disorders that are 
collectively termed as tauopathies. In the next section, we will briefly discuss a few of the known 
tauopathies, with more attention given to Alzheimer’s disease since it is the most prevalent of all 
the known tauopathies.      
2.3. Tauopathies 
 In 1907, Alois Alzheimer presented his paper ‘On a peculiar disease of the cerebral cortex’ 
in which he described neurofibrillary tangles (NFTs) and senile plaques as pathological changes 
associated with presenile dementia [118], utilizing a silver staining technique developed by Max 
Bielschowsky and Korbinian Brodmann [35]. Half a century later, ultrastructural investigations 
made by Kidd, Terry and Crowther revealed that the NFTs are essentially made of double helical 
stacks called “paired helical filaments” and to a lesser extent by straight filaments [117-119]. In 
the mid-1980s, hyperphosphorylated tau protein was found to be the major component of PHFs, 
and this was confirmed by biochemical studies conducted on isolated NFTs from AD brains [120, 
121]. Subsequent studies revealed that, not only in AD, but many progressive neurodegenerative 
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disorders such as frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP 
17), chronic traumatic encephalopathy (CTE), progressive supranuclear palsy (PSP), corticobasal 
degeneration (CBD), Pick’s disease (PiD) are pathologically defined by tau aggregates or toxic 
oligomers of tau [122-124].  
 The diseases where toxic oligomers of tau play a major role in neurodegeneration are 
collectively termed as tauopathies. Tauopathies can be differentiated based on the morphology of 
the tau aggregates, propagation of the aggregates, cells affected and their location in the brain, the 
ratio of tau isoforms and the symptoms observed in the affected individuals [125]. 
2.3.1. Frontotemporal dementia with Parkinsonism and progressive supranuclear palsy 
 In the late 1990s, mutations in the gene encoding tau were demonstrated to cause 
frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP-17). FTDP-17 was 
found to be associated with hyperphosphorylated filamentous inclusions of tau which were 
sufficient to cause neurodegeneration with dementia [117, 118]. PSP is a form of Parkinsonism 
which is characterized by NFTs (fibrillar inclusions found inside the cytoplasm of the cells) and 
neuropil threads (found in the dendrites which get swollen due to the accumulation of tau filaments 
and also found in the distal axons/terminals). NFTs and neuropil threads found in PSP are made 
of straight filaments and paired helical filaments which consists of hyperphosphorylated tau in 
neurons and glia of subcortical and cortical structures and are mainly composed of 4R isoforms of 
tau [126]. 
2.3.2 Pick’s disease (PiD) 
 Pick’s disease (PiD) is another type of tau-related dementia. PiD is characterized by 
difficulty with language and thinking, unwarranted anxiety and behavioral changes. Mutations of 
the tau gene have been observed in PiD [127]. The abnormal tau aggregates form round inclusions, 
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termed Pick's bodies, that are localized near the nucleus. Generally, the tau filaments found in PiD 
are primarily straight filaments composed of 3R tau isoforms [128].  
2.3.3. Corticobasal neurodegeneration (CBD) 
 Corticobasal neurodegeneration or CBD is a neurodegenerative disorder that is 
characterized by asymmetrical cortical dysfunction. Abnormal accumulation of 
hyperphosphorylated 4R tau isoforms, similar to the NFTs seen in PSP and Alzheimer’s disease 
are found in patients with CBD.  Patients with CBD suffer from motor neuron degeneration which 
leads to akinesia, stiffness of limbs, asymmetric involuntary movements, and other complications 
[129]. 
2.3.4. Alzheimer’s disease (AD)  
 AD is the 6th most common cause of death and is also the most expensive disease in the 
USA [130]. It is an irreversible progressive chronic neurodegenerative disorder that impairs 
memory and cognitive skills. Over time, patients find it difficult to carry out the simplest tasks 
such as remembering their name or trying to find their way back home from their backyard. 
Episodic memory deficits or short-term memory losses occur for the first three to six years in the 
initial stages of the disease. Difficulty in the retrieval of old memories and difficulty in speech are 
commonly observed in the later stages, followed by visuospatial impairment in the advanced stages 
of the disease [129- 133]. 
 Approximately 5.5 million Americans are living with Alzheimer’s disease today. Care for 
Alzheimer’s disease affected patients and patients with other dementias has been estimated to cost 
$277 billion per year and the costs are expected to rise to $1.1 trillion by 2050 [130].  
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 The most common form of AD is Late Onset AD or LOAD, in which patients begin 
showing symptoms after the age of 65 years, while in early onset AD or EOAD which accounts 
for about 5% of the cases, age of onset generally lies between 30 and 65 years of age [133].  
Genetically, AD is divided into two groups – familial AD and sporadic AD [133]. Familial 
AD are cases of EOAD and are due to rare genetic mutations in one or more genes that encode 
proteins such as amyloid precursor protein (APP gene), presenilin 1 (PSEN1 gene) or presenilin 2 
(PSEN2 gene) [129, 134]. APP is a transmembrane protein expressed at high levels in the brain. 
Cleavage of APP by  site APP cleaving enzyme 1 (BACE1) and  secretase in the brain results 
in the formation of amyloid  peptides which are one of the pathological hallmarks of AD [135].  
APP can be cleaved by two pathways [136]. In one of the pathways which is called the 
non-amyloidogenic pathway, cleavage of APP takes place by  and  secretases [136]. This 
produces soluble APP peptide which stimulates nerve growth factor and in turn influences the 
production of acetylcholine which is an important neurotransmitter dealing with memory and 
cognitive functions [136]. However, cleavage of APP by both  and  secretases produces amyloid 
 peptide fragments. Cleavage by  secretase at different positions of APP results in C terminal 
heterogeneity in the peptide population [136]. A peptide cleaved at position 40, called A40, is 
the most abundant Aβ product in the brain followed by the peptide cleaved at position 42, called 
A42. A42 is more hydrophobic, and along with A40 forms long insoluble fibrils in the brain 
[135]. Presenilins 1 and 2 regulate the proteolytic function of  secretase, and mutations in the 
genes PSEN1 and PSEN2 can disrupt the ratio of A42 to A40 in the brain, resulting in early 
onset of AD [34]. 
The sporadic form accounts for 95% of AD cases and is generally late onset. It most likely 
results from a combination of genetic and environmental factors [137]. The most common genetic 
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risk factor in sporadic AD is the presence of 4 allele of apolipoprotein E [138]. ApoE is the 
dominant lipid and cholesterol carrier in the brain and it is involved in A clearance or catabolism. 
The human ApoE gene consists of 3 polymorphic alleles - 2, 3 and 4 - which have a worldwide 
frequency of 8.4 %, 77.9% and 13.7%, respectively [138]. However, in AD patients the 4 allele 
is seen to be approximately 40%. Expression of ApoE 4 increases the risk of AD [139]. 
 AD is described by two underlying neuropathological hallmarks - NFTs formed by 
hyperphosphorylated aggregates of tau, and senile plaques formed by aggregation of A peptide 
[140, 141]. There are indications that tau and  amyloid might work together to drive neurons to a 
diseased state which finally results in neurodegeneration [142]. Although how both proteins 
influence each other’s functions is a matter of debate, as both of them can form aggregates and 
spread through the brain by themselves and function independently of one another.  
The amyloid cascade hypothesis (ACH) was developed because it was noted that amyloid 
 peptides were the main constituents of senile plaques, and because mutations in APP and other 
associated proteins resulted in early onset of AD. According to amyloid beta cascade hypothesis 
(ACH), accumulation of amyloid beta peptide acts as the main trigger for AD. It was suggested 
that A plaques influence tau to form toxic oligomers [143]. In one study with transgenic mice 
overexpressing human P301L tau, the injection of A42 resulted a five-fold increase in NFTs near 
the injection sites [144]. In another experiment conducted by Lewis et al., JNPL3 transgenic mice 
expressing mutant tau were crossed with Tg2576 transgenic mice expressing mutant  amyloid 
precursor protein. In the progeny, A deposits developed at the same age as parental controls, 
however NFT pathology was enhanced in the double mutant progeny strain [145]. These examples 
are two of many studies conducted that suggest A triggers tau pathology. Because of these 
experiments and others contributing to the amyloid cascade hypothesis, A was considered to play 
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a key role in AD pathogenesis upstream of tau pathology. Therefore, along with the genetic 
mutations in APP and other associated proteins, A was considered to be the prime target for 
developing therapeutics for treating AD pathology. Promising immunotherapies such as 
monoclonal antibodies, solenazumab and bapineuzumab, that target A pathology, failed to 
achieve cognitive and functional endpoints in phase 3 of clinical trials [146, 147]. In 1991, staging 
of AD-related neuropathology was described by Braak and Braak using the brain distribution of 
NFTs. NFTs and neuropil threads seem to follow a characteristic distribution pattern that directly 
correlated with cognitive impairment in the brains of deceased AD patients [148, 149]. In 2007, 
Roberson et. al., observed that reducing tau content blocked A and excitotoxin-induced neuronal 
dysfunction in vivo [150]. In a similar study, it was demonstrated that knocking out endogenous 
mouse tau genes in transgenic mice expressing human mutated APP and PS1 protected the mice 
against memory loss, cognitive impairment and synaptic loss [151]. The tau knockout mice model 
also had less plaque content than APP/PS1 transgenic mice model. This study also showed that 
reducing tau levels prevented behavioral deficits in transgenic mice expressing APP without 
altering A [150]. This study along with the previous work by Roberson et al., demonstrated the 
feasibility of the argument that tau is necessary for A pathology [150]. It was also demonstrated 
from tau knockout mice models that knocking out tau aggregates protects against synaptic loss. 
Therefore, with respect to these experiments it was suggested that pathological tau is indeed toxic 
to the neurons.  Therefore, it has been hypothesized that targeting tau pathology might inhibit the 
formation of tau aggregates and development of tau-targeting therapeutics can provide protection 
against memory impairment as well as potentially reverse AD pathology. Whether A  influences 
the production of toxic forms of tau or vice versa is still a much-debated topic.  
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AD is one of the most common causes of death in the USA, yet there are hardly any 
therapies which could reverse or inhibit the pathology of the disease. In the next section, we will 
discuss the challenges that are faced in treating AD and other tauopathies. 
Chapter 3. Challenges in treating AD and other tauopathies 
3.1. Lack of proper diagnosis 
 One of the major problems with AD or other tauopathies is the difficulty in diagnosing 
affected patients as no single effective tool exists that can give a definitive result indicating 
whether a person is suffering from any of the known tauopathies [152]. Given the similarity in the 
symptoms of different tauopathies, it becomes even more difficult to diagnose the type of dementia 
one person is suffering from. Cognitive tests such as the mini mental state examination [153], or a 
list of words memorized to be recollected later, or the clock drawing test [154], are not efficient 
methods of testing since a blind person, or a person who is deaf and mute, or does not know how 
to read can perform poorly in these tests despite not suffering from dementia .  
 Recent technology has introduced brain imaging techniques which can be used to look at 
the structure and function of the brain. MRI/CAT scans can be used to study the structure of the 
brain by measuring the brain volume and PET scans can give us data which are helpful in studying 
brain function [155-157]. Current molecular imaging techniques utilizing PET scans are a step 
towards successful diagnosis of many neurodegenerative disorders [157-160]. PET scanning 
makes use of small molecular weight compounds such as Pittsburg compound B (11C-PIB) which 
can bind to A peptides, and emit radiation allowing for visual and quantitative measurement of 
A deposition [161]. 11C-PIB compound is one of the most widely studied amyloid radioligands 
which is used to study the amyloid  plaques found in AD by PET imaging. Compared to a control 
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population, the propensity of this radioligand to bind in AD patients increases by 50% due to the 
increased levels of A peptide [148, 149]. Other radioligands approved for  amyloid PET imaging 
include 18F-florbetapir and 18F-flutemetanol [160]. 18F-FDDNP(2-(1-(6-[2-fluorine 18elabelled 
fluoroethy)methylamino]-2-napthyl) ethylidene)malononitrile) is a tracer molecule which can be 
used for both  amyloid and tau pathology [162]. Currently, another compound 18F-AV-1451 and 
18F-T807 is in clinical phase development as a PET tracer for in vivo imaging of tau aggregates 
[160, 162]. These techniques will not only help elucidate the degree of pathology but also 
potentially allow better diagnosis.  
3.2. Lack of effective therapies 
 The second and major drawback in treating AD or other tauopathies is the lack of any 
efficient, commercially available drugs that are directed towards treating the underlying causes of 
the disease. Due to the prevalence of AD over other tauopathies, most of the research conducted 
over the years has been directed towards finding a cure for AD rather than other tauopathies. Most 
of the drugs available for AD (Table 1) are directed towards facilitating communication at synapses 
[163-165] of the neurons, as destruction of the synapses is widely observed in several 
neurodegenerative disorders such as AD [166]. 
Chapter 4. Current treatments 
4.1. Current approved therapies for AD and other tauopathies 
 The currently available drugs approved by FDA (Table 1) are the cholinesterase inhibitors 
donepezil, galantamine, and rivastigmine, and the NMDA receptor blocker memantine. These 
drugs have been used to treat the cognitive symptoms associated with AD and can be effective for 
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a certain amount of time [167]. The biggest drawback of these drugs is that the cognitive functions 
of patients gradually decline as soon as the drugs lose their effectiveness. 
 
Table 1: FDA approved drugs for treating AD and other tauopathies 
 
 
4.1.1. Acetylcholinesterase inhibitors 
 Acetylcholine is an important neurotransmitter involved in memory retention [168] and 
other memory related functions. Acetylcholine transmits signals from one cell to the other. Once 
the message has been delivered, acetylcholine is broken down by an enzyme known as 
acetylcholinesterase. Acetylcholinesterase helps remove acetylcholine from the synaptic cleft, 
terminating the signal [165].  In AD, cholinergic neurons producing acetylcholine are destroyed 
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and acetylcholine levels in the brain are reduced. Acetylcholinesterase inhibitors such as Donepezil 
(brand name: Aricept) was the first approved drug for AD. It was approved by the FDA in 1996. 
Donepezil, in common with other cholinesterase inhibitors, reduces the rate at which 
neurotransmitters are broken down, thereby delaying the loss of cognitive symptoms and the onset 
of dementia. In some of the AD patients, rivastigmine, an example of another acetylcholinesterase 
inhibitor, may improve memory and awareness [169]. It has been used to treat neuropsychiatric 
symptoms in CBD, however it does not affect cognition. 
4.1.2. NMDA receptor antagonist - Memantine 
 In AD patients, an excess amount of glutamate has been observed [170]. Glutamate is a 
major excitatory neurotransmitter [171]. It functions by transmitting messages from one neuron to 
the other [172]. When glutamate or glycine binds at the glutamate binding site, the N-methyl-D-
aspartate (NMDA) receptor gets activated and allows the transmission of positively charged ions 
through the ligand-receptor gated channel [172]. Therefore, the excessive glutamate present in AD 
binds to the NMDA receptor and the gated ion channel remains open which allows a constant flow 
of positively charged ions [172]. Memantine is a partial uncompetitive NMDA receptor antagonist 
that can reduce the action of glutamate [173, 174], and decrease glutamate excitotoxicity 
associated with AD [158].  
 All the 5 drugs (Table 1) have a variable effect on different people with AD. Most of these 
drugs have side effects for different patients and might not work at all for many people. Although 
in a few patients, they may slow down the process of disease progression or worsening of the 
symptoms for a while, the underlying pathology is not slowed, and the disease progression 
eventually goes back to its initial rate [159].  
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4.1.3. Selective serotonin reuptake inhibitors (SSRI) 
 In open label cases or in case reports, it has been demonstrated that SSRIs have been able 
to decrease neuropsychiatric symptoms such as disinhibition and repetitive stereotypical behavior 
[175]. It can also be used to treat food craving, inappropriate sexual behavior and aggressiveness. 
This is used to treat depressive symptoms in CBD, PSP and dementia with Lewy bodies [176]. 
4.1.4. Combination of the available FDA approved drugs 
 No evidence has been found which clearly indicates that combining all three different 
cholinesterase inhibitors - donepezil, galantamine and rivastigimine (Table 1) would yield better 
results. Rather more discomfort is apparent as more side effects have been observed in patients 
taking a combination all three cholinesterase inhibitors [167, 177].  
 However, if Aricept is taken along with Memantine the rate of disease progression is slower 
[177]. This is a temporary treatment and over the course of time, disease progresses, and condition 
of the patients worsens.  
4.2. Current experimental tau-based therapies for AD 
 Given the inefficacy of the currently available FDA approved drugs to arrest the 
progression of the disease, research is focused on developing further treatments and small 
molecules that target the underlying cause or the pathological hallmarks of AD. The 
neuropathological hallmarks strongly influence the recent AD therapeutic approaches. Without 
drugs efficiently working against the neuropathological hallmarks -  amyloid plaques and NFTs, 
the cost of treatment and care for AD has been estimated to increase to 1.1 trillion dollars by the 
year 2050, and the health of patients will decline due to progression of the disease [130]. After the 
failure of 19 drugs targeting A  pathology in clinical trials, greater attention is focused on 
reducing tau pathology [146].  
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 Treatments for tau are broadly classified to the five groups namely: (a) tau-centric active 
and passive immunotherapy, (b) microtubule stabilizing agents, (c) tau protein kinase inhibitors, 
(d) tau aggregation inhibitors, and (e) oligonucleotide treatments for tau aggregates. 
4.2.1 Tau centric active and passive immunotherapies  
 Efforts have been made to create safe and effective active and passive vaccines for tau. In 
passive immunotherapies, exogenous antibodies are introduced to the AD affected patients. In 
active immunotherapies, the body’s immune system is stimulated to produce anti-tau antibodies to 
destroy the toxic oligomers of tau. The first active tau vaccine to enter clinical trials was AADvac1 
(Axon peptide 108 conjugated to KLH, Axon neurosciences, Bratislava, Slovak Republic). It is a 
synthetic peptide derived from amino acids 294 to 305 of tau sequence coupled to keyhole limpet 
hemocyanin (KLH) through an N-terminal cysteine and administered through Alhydrogel alum 
adjuvant. Initially the safety of administering the vaccine was evaluated. AADvac1 was designed 
to target misfolded tau in AD and its tolerability and efficacy in participants has been evaluated in 
a phase 1 clinical trial conducted in 3 centers in Austria on patients with mild to moderate AD 
[178]. A subsequent phase 2 clinical trial with 185 participants is underway and the primary 
outcome of the results will be a test of the safety of the drug to the participants and to see if it 
elicits a hyperallergic response from the immune system [179].  
 The vaccine ACI-35 is a 16 residue peptide that includes the phosphorylated residues S396 
and S404, and provides active immunization [179, 180]. It elicits a rapid immune response in 
P301L mice with a mild reduction of hyperphosphorylated tau pathology. Increased IgG titers and 
improved motor function were observed in vaccinated P301L mice model [180]. Currently, a phase 
I clinical trial is running for this active vaccine to assess safety profile along with secondary 
outcomes which includes biomarkers, functional and clinical changes.  
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 Example of passive immunotherapy is administering compound RG7345. It is a human 
monoclonal antibody targeting specific tau phosphorylated epitope at site S422 which is 
predominant in neuronal dendrites [181, 182]. It demonstrated reduced tau pathology and 
intracellular clearance of tau antibody complexes in a triple transgenic mice model of AD and is 
undergoing a phase 1 clinical trial [181].  
 Recently, another new humanized tau monoclonal antibody called armanezumab has been 
developed which is specific to the N terminal region of pathological tau. It was tested against full 
length recombinant tau as well tau isolated from the brains of AD patients. When armanezumab 
was used on SH-SY5Y neuroblastoma cells, it demonstrated its ability to inhibit tau toxicity. It 
also reduced phosphorylated tau and total tau content in tau (P301S)/Tg mice [183]. Currently, no 
clinical trials have been performed with armazenumab, and therefore its efficacy to cross the blood 
brain barrier and protect the cells against tau toxicity in human brain cannot be evaluated. 
However, the discovery of such antibodies are opening up avenues for more research with tau 
directed immunotherapy. 
 
4.2.2 Microtubule stabilizing agents  
 Among other tau based anti-AD drugs, multiple microtubule stabilizing agents have been 
tested. The purpose of developing microtubule stabilizing agents was to create a drug which could 
stabilize microtubules in the absence of tau protein. Dissociation of tau from microtubules result 
in axonal transport impairment and synaptic dysfunction. Some compounds such as paclitaxel, 
epothilone D or TPI 287 were used in transgenic AD mice models. In a preventive study, 
epothilone D was administered to young PS19 tau transgenic mice which initially lacked tau 
pathology. With age, while the untreated mice developed axonal microtubule loss, dystrophy and 
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spatial learning deficits, epothilone D treatment reduced these changes [184].  In another study, 
administration of epothilone D in PS19 mice model reversed behavioral and cognitive deficits and 
cleared tau pathology in the mice [185]. However, due to the absence of results from the majority 
of the drugs targeting microtubule stabilization, along with the presence of toxic side effects the 
studies were halted for AD [186].  
  Another microtubule stabilizing agent named davunetide, which is an eight amino acid 
peptide derived from activity-dependent neuroprotective protein (ADNP), has demonstrated its 
potential to decrease A and hyperphosphorylated tau levels in ADNP knockout mouse models 
[187]. In spite of the encouraging results obtained through a variety of tests, phase II and III results 
demonstrated the inefficiency of davunetide with pure tauopathy PSP, which halted its 
development.  
4.2.3 Tau protein kinase inhibitors 
 Post translational modification, especially phosphorylation, of tau is a common event even 
in normal brain. However, in AD patients, abnormal phosphorylation of tau is observed [21]. This 
abnormal phosphorylation in AD patients results in a disturbance of the balance between kinases 
and phosphatases in the brain. Abnormal phosphorylation is one cause of the disassociation of tau 
from microtubules [13]. Efforts have been made to develop kinase inhibitors which can balance 
the number of kinases and phosphatases present in the AD brain. A GSK-3 inhibitor called 
tideglusib was in clinical trials for AD and progressive supranuclear palsy [173]. In a Phase IIa 
trial, it was orally administered to 30 patients with a dosage of 400-1000 mg/day for 20 weeks. 
Positive outcomes such as better cognitive ability was observed.  Four out of 5 groups of patients 
with mild to moderate AD had significantly better response on Mini Mental State Examination 
(MMSE) [188]. Unfortunately, in a phase IIb clinical trial, conducted to assess safety and efficacy 
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of tideglusib in mild to moderate AD patients, no statistically significant different outcomes were 
observed in AD patient receiving tideglusib with respect to the AD patient group placed on placebo 
[189]. Moreover, diarrhea and asymptomatic transaminase elevations were seen as side effects. 
There are no current approved trials undergoing with tideglusib. Another alternative approach for 
targeting tau phosphorylation could be activation of phosphatases which could reduce 
phosphorylation of tau and restore the balance of kinases and phosphatases in the AD brain. One 
of the candidates for phosphatases is PP2A, but clinical trials has not been started yet with them 
[41, 62].  
4.2.4 Tau aggregation inhibitors (TAI) 
 In order to learn about tau aggregation kinetics and how viable tau aggregation inhibitors 
are, it is necessary to induce tau polymerization in vitro. 
4.2.4.1. In vitro tau polymerization 
 In vitro tau polymerization can be obtained by addition of inducer molecules such as 
polyanionic compounds. For example, glucosaminoglycan heparin [78], polyglutamate [175, 
190[190] and RNA [191], and fatty acids or fatty acid like molecules such as arachidonic acid 
[192], docosahexaenoic acid [193] and alkyl sulfonate detergents [194] have been used to induce 
tau aggregation. The mechanism by which these compounds facilitate polymerization has not yet 
been fully elucidated. It is hypothesized that negative charge on the polyanionic inducer molecules 
might be a reason why aggregation of tau molecules take place, as the relatively positively charged 
carboxy terminal of tau can bind to the negatively charged anionic molecules. The negative charges 
on the polyanionic inducers and tau binding to the inducer molecules can result in an “induced fit” 
conformation to the microtubule binding regions of tau similar to the model proposed for tau 
binding to microtubules [195]. Higher levels of arachidonic acid are observed in brains of AD 
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patients [5]. It has been observed that fatty acid inducer compounds such as arachidonic acid 
induce tau aggregation [194]. Although the tau fibrillization that takes places under the influence 
of arachidonic acid resembles straight filaments, they mimic the characteristics of PHFs commonly 
found in AD [196].  
 Native tau does not readily form secondary or tertiary structure.  Therefore, the change of 
conformation of soluble tau into insoluble highly ordered aggregates of tau filaments has been a 
mystery for scientists for a long time. Thus, the ability to be able to form aggregates of tau in vitro 
have allowed scientists to learn more about the pathological forms of tau found in AD and other 
tauopathies. Also, as tau aggregation occurs rapidly in vitro with the help of inducers, it can be 
used to study the efficiency of various tau aggregation inhibitors. The knowledge gained from 
these experiments can be used in the formulation of therapeutics and testing them in order to 
evaluate their efficacy before conducting in vivo studies.  
4.2.4.2. Tau aggregation inhibitor-based therapies 
 Several tau-directed approaches for treating AD have been developed. However, in cell-
based and in vitro assays, small molecular weight compounds such as tau aggregation inhibitors 
(TAIs) have shown the ability to inhibit aggregation of tau proteins and some have already been 
tested in humans. Several classes of tau aggregation inhibitors have been isolated from plants, 
fungi, or have been chemically synthesized. Chemical compounds such as polyphenols [197, 198], 
porphyrins [198], phenothiazines [198], benzothiazoles, azaphilones [199], and anthraquinones 
[200] are a few of the many classes of compounds which have shown a tendency to prevent tau 
aggregation in vitro studies. All these compounds share the common structural motif of containing 
at least one aromatic ring structure. TAIs can be broadly categorized into two groups – covalent 
TAIs and non-covalent TAIs.  
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 Covalent TAIs function in one of two ways. They can either covalently modify tau, or they 
can lead to the formation of bonds between different tau molecules, or between different sites on 
the same molecule. In either case, these TAIs lead to tau molecules that are unable to aggregate 
[186, 201]. Natural products such as oleocanthal [202], oleuopeinaglycone [203], and 
epigallocatechin gallate (EGCG) [204], are some well-known and studied covalent TAIs. 
Oleocanthal reacts with epsilon groups of lysine residues including the residues present in the 
MTBR to form imines [202, 205]. 
 
Figure 5: Methylcobalamin from Vitamin B12 
 Vitamin B12 is also categorized as a tau polymerization inhibitor. Vitamin B12 deficiency 
is linked to inactivation of PP2A and therefore, subsequent phosphorylation and aggregation of 
tau protein [206]. It has been hypothesized that vitamin B12 binds to tau protein apart from playing 
a role in activating PP2A [207-209]. The addition of methylcobalamin (Figure 5), the active form 
of vitamin B12, to monomeric tau resulted in quenching of tyrosine fluorescence (tyrosine is the 
only fluorophore in tau protein, the ring structure of tyrosine enables the electrons to reach higher 
resonating states upon excitation with light) at 304 nm and also at 360 and 405 nm [206]. Such 
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spectroscopic changes are observed due to the interaction of methylcobalamin with the thiol groups 
and formation of thiolactocobalamine, which might suggest that there are intermolecular 
interactions with cysteine residues of tau [206]. To validate the hypothesis that there are cysteine 
interactions of tau, the authors used cysteine blocked tau with methylcobalamin and observed no 
spectroscopic changes at 360 and 405 nm.  This data reinforced their hypothesis that vitamin B12 
binds to the protein tau via interaction with the cysteine residues. From these experiments, it could 
be concluded that tau binds to vitamin B12 via interaction at the cysteine residues to form a 
tau/vitamin B12 complex that hinders the formation of stacking of tau monomers and formation 
of fibrils [206]. However, all these experiments were performed in vitro and hence it is yet 
unknown whether vitamin B12 will show the same efficiency against tau aggregates in vivo.  
 
Figure 6: Structure of LMTX 
In recent years, methylene blue (MB) or methylthionium chloride has been repurposed as 
medical treatment for tau pathologies [210]. In 1996, Wischik et al. reported phenothiazines such 
as methylene blue reverse the proteolytic stability of the protease-resistant tau aggregates by 
inhibiting the tau-tau interaction at the hexapeptide motifs of the MTBR domain [211]. MTC is a 
tricyclic phenothiazine derivative which exists in equilibrium between reduced LMT (leuco-
mrthylthionium chloride) and oxidized form (MT+) [212]. MTC has been used previously to treat 
malaria, methemoglobinemia and depression [213]. Due to its long history of prior clinical use, it 
was used in tau aggregation inhibitor studies. MTC efficiently crosses the blood brain barrier and 
selectively penetrates neurons – particularly the hippocampal cells after systemic administration. 
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In various studies, MTC has shown to interfere with the tau-tau binding that is required to form 
aggregates. However, there are fewer results reported for efficacy in tau-tau aggregation in in vivo 
studies. In a recent study, 6 weeks of oral treatment with MTC did not show reversal of the NFT 
pathology in the transgenic AD mouse model rTg4510, which develops a robust tangle pathology 
[214]. But even though scientists failed to obtain positive results in cases where MTC was 
administered in the presence of preformed filaments, MTC reduced tau levels without affecting 
the insoluble tau levels in JNPL3 (P301L) transgenic pretangle mice [215].  This showed that MTC 
can reduce the soluble tau levels when insoluble aggregates have not yet formed and thus has 
potential for further studies [186]. Reduced forms of MTC are functionally stable in the human 
brain. However, it is not easy to obtain the reduced form of MTC. A stable reduced version of 
MTC (leucomethylthioninium with a suitable counter ion, LMTX or Trx0237) (Figure 6) has been 
developed which has better tolerability and absorption than MTC. Trx0237 is the successor of 
Rember which is a methylthionium chloride (MTC) derivative compound. [171] LMTX or 
Trx0237 is currently undergoing clinical trial phase 3 [216, 217].  
The second class of TAIs, the noncovalent TAIs, interact with tau species non-covalently 
through multiple mechanisms and with multiple different structures [210, 218]. However, the 
mechanism by which most of the TAIs work has not yet been elucidated. The cross  spines share 
a common structural feature which is termed a “steric zipper” where side chains from the two  
sheets form a tightly interlocking dehydrated interface such that the resulting  sheet bilayer forms 
a fundamental building block of fibrillary aggregates [219]. It has been hypothesized that non-
covalent TAIs may block the formation of steric zipper structures (which play a role in the 
formation of the  sheets) or that they can influence reconfiguration of the tau molecule. 
 38 
Apart from MTC derivatives, which have gained attention over the past few years, there 
are other small molecules which are naturally or synthetically derived and could be developed as 
commercially available potential tau aggregation inhibitors. Several synthetic and natural products 
with the common structural feature of containing at least one aromatic ring have recently gained 
attention due to their ability to inhibit tau aggregates induced by heparin or by arachidonic acid in 
vitro. 
 
Figure 7: Structure of PE859, a curcumin derivative 
One such TAI is PE859 (a curcumin derivative) which was observed to inhibit heparin 
induced full length tau and 3R tau oligomers in vitro (Figure 7) [220]. The IC50 (the concentration 
of compound required to provide 50% inhibition of tau aggregation) for full length tau and 3-repeat 
tau with PE859 is 2.23 M and 0.81 M respectively [220]. This suggests that smaller doses of 
PE859 can induce disassembly as well as inhibit the formation of tau aggregates as lower doses 
can get easily absorbed by the immune system and it can be expected that it will not induce any 
unexpected unwanted immune response which might have adverse side effects. Upon evaluation 
of rotarod performance of JNPL3 mice placed on placebo along with JNPL3 mice on oral 
administration of PE859, it was observed that the JNPL3 mice dosed with PE859 had less decline 
in motor coordination compared to untreated mice [220]. Therefore, PE859 might have played a 
role in delaying onset and progression of the motor dysfunction. With further investigation, it was 
also found that mice receiving a dosage of PE859 had lower accumulation of sarkosyl insoluble 
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tau as well as sarkosyl soluble tau [220]. This result suggested that PE859 showed significant 
decrease of tau aggregates and resulted in improvement of motor function [220]. Orally 
administered PE859 was absorbed in blood and 80% of PE859 in blood was transferred to brain, 
suggesting that PE859 can cross the blood brain barrier and hence can be modified into a drug for 
CNS disease [220]. However, high doses of PE859 such as 40 mg/kg had to be administered to the 
mice. Such high doses might elicit an unknown response from the human immune system as the 
immune system could treat such high amounts of drugs as antigens and degrade them even before 
they reach the brain. PE859 has not yet been tested on human subjects and therefore, the possibility 
of development of this small molecule into a drug is yet to be studied. 
 Studies conducted by Comejo et. al., have observed that rosmarinic acid (Figure 7) prevents 
tau fibrillization by preventing the assembly of the  sheet structure during the formation of tau 
aggregates [221].  Rosmarinus officianalis L. belongs to the Lamiaceae family and has been used 
as an anti-inflammatory and antimicrobial agent [222, 223]. Five compounds were isolated from 
R. officianalis and all of them were demonstrated to inhibit tau aggregates, but one of the five 
compounds, named compound 5, was observed to be the most efficient of the compounds. It was 
also observed that formation of tau aggregates was inhibited due to the interaction of compound 5 
with the  sheets [221]. Although, this study demonstrated the ability of derivatives from 
rosmarinic acid to inhibit tau aggregation, the interaction of compounds with the microtubules and 
its effect on the stabilization of microtubule by tau has not been evaluated by the authors. 
Therefore, even though compounds from rosmarinic acid are exciting as TAIs, the possibility of 
this compound to be modified as a potential drug candidate remains to be seen. 
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Figure 8: Structure of rosmarinic acid from which compound 5 was isolated. 
 Fulvic acid (Figure 8) has a variety of nutraceutical properties and is one of the most 
interesting naturally-occurring phytochemicals with its extremely high antioxidant properties and 
apparent neuroprotective effect [224-226]. Fulvic acid when used against tau aggregates induced 
by heparin showed inhibition in formation of tau aggregates as well as it is able to disassemble 
preformed tau fibrils [224]. Therefore, fulvic acid is a promising compound and subsequent studies 
have to be performed in order to learn about the efficacy of fulvic acid against tau aggregation in 
vivo.  
 
Figure 9: Structure of fulvic acid 
Compounds from the family of anthraquinones such as emodin (Figure 9), daunorubicin, 
and Adriamycin, inhibit PHF formation and disassemble tau aggregates induced by heparin, in 
vitro at IC50 and DC50 values in the low micromolar range. IC50 and DC50 values in this range 
suggest that smaller concentration of these compounds could inhibit formation of tau aggregates 
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as well as disintegrate pre-formed aggregates, respectively. These compounds were observed not 
to interfere with the stabilization of microtubules by tau either [227]. Fungi are known to produce 
natural products which have been a rich source of compounds with medicinal properties. In nature, 
fungi such as Aspergillus nidulans produce secondary metabolites that are enriched with anti-
amyloid properties to compete with biofilms (major building blocks of which are amyloid 
aggregates) produced by bacteria [228]. Although, amyloid proteins differ in sequence, the 
amyloid fold has common structural features that extend across diverse proteins. Thus, it can be 
hypothesized that fungal compounds that have anti-amyloid activity can be used to develop 
compounds which can inhibit tau aggregation. Paranjape et al. conducted studies with secondary 
metabolites isolated from A. nidulans which were screened for compounds with ring structures for 
their ability to inhibit tau aggregation induced by arachidonic acid in vitro [229]. Among the 
compounds tested, 2, ω-dihydroxyemodin, asperthecin, and asperbenzaldehyde were found to be 
the most efficient inhibitors of tau aggregation [229]. 2,ω-dihydroxyemodin and asperthecin have 
similar structures but asperbenzaldehyde represented a new class of TAI (Figure 10). Additionally, 
asperbenzaldehyde can be converted to azaphilone compounds, some of which have strong 
lipoxygenase inhibitor activity [199, 229]. Eleven azaphilone compounds were generated by semi-
synthetic diversification of asperbenzaldehyde and screened for tau aggregation inhibition activity 
[184]. A subset of these compounds, namely aza-8, aza-9 (Figure 10), aza-12 and aza-13 could 
inhibit the formation of tau aggregates and could disassemble pre-formed tau aggregates [199]. 
Additionally, 4 of these compounds have lipoxygenase activity which could reduce fatty acid 
metabolites of arachidonic acid and docosahexaenoic acid that are elevated in AD [230]. 
Therefore, these compounds exhibited the ability to inhibit the formation of tau aggregates as well 
as reduce preformed tau aggregates and could partially preserve tau’s ability to bind to tubulin and 
 42 
promote microtubule assembly, and therefore they could be used to develop a novel scaffold for 
TAI molecules [199]. 
 






Figure 11: Structures of asperbenzaldehyde and aza-9 which is derived from its precursor asperbenzaldehyde. 
 
4.2.5. Oligonucleotide treatments for tau  
 Oligonucleotide therapy has been developed over a long period of time and drugs for two 
neuromuscular diseases has been recently approved by the FDA. In oligonucleotide therapy, anti-
sense oligomers that mimic the targeted mRNA are synthesized which will bind to the mRNA 
encoding a target protein. It destroys the mRNA encoding for the protein and therefore, there is an 
overall reduction in the content of the target protein [231]. 
Recently, oligonucleotide treatments for tau have been proposed. Scientists from 
Washington University School in St. Louis have used a drug named as TauASO12 on PS-19 mice 
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models which overexpresses P301S tau. They delivered TauASO12 via a tiny osmotic pump which 
funneled the oligonucleotide directly into the mice brain. They stopped the treatment after a month 
and then they checked the brain tissues after 2 months. They found less tau pre-mRNA in the mice 
models and in some cases, it also reversed the neurological damage [231]. Therefore, developing 
antisense oligonucleotides reducing tau content in the brain is a promising technique which can be 
used for the future development of tau directed therapies.  
Chapter 5. Conclusion 
 The A cascade hypothesis has played a critical role in the types of drugs that have been 
developed for AD for many years. It is still believed by some that if A deposits could be removed 
from the brain, AD pathology could be prevented. However, with the failure of several anti-A 
drugs in clinical trials along with data suggesting that tau aggregation can independantly result in 
many neurodegenerative disorders, more emphasis is being placed on the development of tau-
directed therapies for AD and other tauopathies [232]. Tau belongs to the class of structural 
microtubule associated proteins, the major function of which is stabilizing and promoting 
microtubule assembly [2]. However, after post-translational modifications, such as abnormal 
phosphorylation or truncation, the protein forms toxic oligomers which reduces its propensity to 
bind microtubules [42]. This results in the formation of NFTs and eventually neurodegeneration. 
Tau based therapies have gained a lot of attention over the past few years due to their efficiency 
in some in vivo models and this has given some hope that tau-based therapies can be used to treat 
AD. 
 Of the different kinds of tau–directed therapeutics developed over the years, using 
immunotherapy is a difficult way to reverse the neurodegenerative pathology. Monoclonal 
antibodies are very specific for the protein species. However, it is not known which phosphorylated 
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protein must be eliminated to stop the onset or progression of AD. In the case of active 
immunotherapy, there is a higher risk of side effects as the antibody is exogenously delivered. The 
antibody might be considered as a foreign particle and subsequently degraded. In passive 
immunotherapies, the human immune system is stimulated to produce the antibodies. This kind of 
therapy will be effective as long as the antibodies are present in the patient’s system. Since this is 
not a permanent technique, patients have to be injected with vaccines routinely for the rest of their 
lives. For a recently developed immunotherapy agent, the sample size used during the first clinical 
trial of AADvac1 was 30 patients and two patients immediately withdrew from the trial due to the 
side effects of the medication. The sample size was too small to evaluate the efficacy of the 
vaccine. Moreover, in the initial trial with the vaccine, one dose was given to the patients and it 
was not enough to evaluate the immune response elicited by the vaccine. Apart from taking into 
consideration all the above stated facts, the failure of immunotherapy targeting A plaques (as 
targeting the plaques could not reverse the AD pathology) have shown that even though 
immunotherapy might seem effective in in vitro and in vivo studies, it might fail in clinical trials. 
Hence, even though AADvac1 and ACI-35 seem to be efficient in vitro and in vivo studies with 
mice models, its effectiveness in the human brain is still unclear [179].  
 Similarly, with microtubule stabilizing agents, they can be used to stabilize the 
microtubules, but the tau aggregates might continue to form. If not properly controlled, 
microtubule stabilizing agents can hinder mitosis of the cell, resulting in cellular death. Also, as 
mentioned previously, abnormally phosphorylated tau and aggregated tau can form toxic species 
that might result in neurodegeneration over the course of time, even with microtubule stabilization. 
 Protein phosphorylation is one of the major post translational modifications which 
determines the functionality of many proteins. Phosphorylation of certain residues are essential for 
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tau to bind to the microtubules. Tau protein kinase inhibitors and phosphatases can be used to 
regain the phosphatase and kinase balance in the brain and reduce the phosphorylation of tau which 
leads to the formation of the toxic forms of tau. But kinase inhibitors have to be very specific for 
the phosphorylated tau they should target. Inhibition of phosphorylation of tau which is necessary 
for tau to bind to the microtubules will be an undesirable effect. Also, phosphorylation occurs on 
many proteins. Therefore, kinase inhibitors might have a detrimental effect if they inhibit 
phosphorylation of proteins other than tau. Phosphatases cause the reduction of 
hyperphosphorylated tau and thus reduce the formation of NFT-like structures and memory 
impairment in animal tau models [233]. Phosphatases have a therapeutic potential to treat AD but 
compounds stimulating phosphatase activity have not yet undergone clinical trials and it is difficult 
to predict its outcome at the current stage.  
 Oligonucleotide treatment for tau targets is directed to reduce or completely remove the 
total tau content in the brain. Because tau binds to tubulins and stabilizes and promotes microtubule 
assembly, the reduction of tau or complete removal of tau protein from the brain might result in 
difficulties in the assembly of microtubules which might give rise to unwanted side effects. 
Delivery of oligonucleotides to the human body is very difficult as they might be treated as foreign 
particles by the immune system and result in its immediate degradation. Hence, the oligonucleotide 
strategy has not yet been well established and thus it’s viability in in vivo models as well human 
subjects has not been determined yet.  
 The most promising therapy for AD is tau aggregation inhibition. As has been discussed in 
the previous section, tau aggregation results in the formation of PHFs and eventually NFTs. Not 
only that, tau aggregates are found to be toxic in nature. They can induce apoptosis of cells and 
can even result in paralysis when expressed in mice models or when tau aggregates are introduced 
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exogenously in mice models. With the success of certain tau aggregation inhibitors in vitro, it has 
become one of the most researched subjects for treating AD and other tauopathies. TAIs have 
proven to be a valuable asset in treating tauopathies since they can disassemble as well as inhibit 
tau aggregate formation in vitro as well as in animal models of tauopathies. Most of the TAIs found 
to be efficient with tau aggregates are derived from natural products. Hence, synthesis and 
production of the TAIs will not be a herculean task if the TAIs can function as is required to control 
the AD pathology. Different TAIs can target different portions of the tau aggregates. For example: 
oleocanthal inhibits fibrillization by blocking tau protein in its natively unfolded conformation 
[202]. LMTs modify tau protein via oxidation of cysteine residues [234]. Other compounds can 
block the formation of the steric zipper structures which are common in peptides forming the  
sheets [235]. 
 Treating AD and other tauopathies is a major challenge in clinical practice. Therefore, 
scientists and physicians are being encouraged to combine different drugs together to treat A 
plaques as well NFTs. When memantine was used with acetylcholinesterase inhibitors, it did not 
prove to be beneficial for the patient [177]. Rather, the side effects were more severe when 
combined drugs were given to the AD patients. One combination therapy consisting of memantine 
and donepezil however showed some evidence of synergistic combination effects of symptomatic 
therapy with combination drugs [236]. When developing new drugs which inhibit tau aggregation 
in AD, any drug that not only inhibits the formation of toxic tau oligomers but also is able to 
disassemble pre-existing tau aggregates (since the patient can get diagnosed with AD after NFTs 
have already started forming), does not interfere with tau’s function of stabilizing microtubule 
assembly and is able to cross the blood brain barrier will be an ideal choice.  
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 However, the role of tau in AD, along with its association with A and its tendency to form 
aggregates, has to be studied more extensively to better understand and develop more drugs and 
therapeutics. Research with TAIs has opened up a new field for exploration for scientists as these 
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